Most Recent
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.
Uber is challenging a ruling that found many email exchanges with its lawyers were made in furtherance of offences and were not protected by legal professional privilege, saying it would be forced to hand over to a class action "bog standard" legal advice.
Settlement talks in a class action on behalf of women injured by allegedly defective pelvic mesh products have failed after Astora Health took a long-standing $27 million settlement offer off the table.
Uber has appealed a ruling that found many of its email exchanges with its lawyers were made in furtherance of offences at the centre of a class action and were not protected by legal professional privilege.
The High Court has granted special leave to a cosmetic company to challenge a judgment finding it infringed Botox maker Allergan's trade marks by marketing its topical creams as Botox alternatives.
Settlement talks in three class actions on behalf of women injured by allegedly defective pelvic mesh products have progressed “substantially”, a court has heard.
The High Court has agreed to weigh in on whether property data analytics firm CoreLogic infringed a real estate photographer's copyright by uploading images from realestate.com.au to its platform.
An additional 1,200 women who were implanted with defective pelvic mesh devices will be eligible for compensation after Johnson & Johnson unit Ethicon agreed that findings in an earlier class action which it unsuccessfully fought all the way to the High Court should apply to a follow-on class action.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.
The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck's patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.